CareDx (NASDAQ:CDNA) Posts Quarterly Earnings Results, Beats Estimates By $0.21 EPS

CareDx (NASDAQ:CDNA) announced its quarterly earnings data on Tuesday. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.21, FiscalAI reports. CareDx had a negative net margin of 5.65% and a negative return on equity of 6.50%. The firm had revenue of $117.70 million for the quarter, compared to the consensus estimate of $102.29 million. During the same period in the previous year, the firm posted $0.09 earnings per share. The firm’s revenue was up 39.3% on a year-over-year basis.

Here are the key takeaways from CareDx’s conference call:

• CareDx completed a planned divestiture of its lab products business for ~$170M upfront to simplify the company and sharpen focus on its core precision testing services and digital/patient solutions, which grew 48% and 33% in Q1 respectively.
• The announced acquisition of Navoris adds a tumor‑naive TTMV MRD/diagnostic platform with Medicare ADLT coverage ($1,800/test), ~130k commercial tests to date, and management’s estimate of a ~$4.5B TAM (with ~$1.5B in MRD), positioning CareDx in HPV‑driven oncology markets aligned with its repeat‑testing model.
• Q1 results showed strong operational momentum with revenue +39% to $118M, testing volume +17%, adjusted EBITDA of $19M (triple‑digit growth), $198M cash, and raised 2026 guidance to $447M–$465M revenue and $43M–$57M adjusted EBITDA, plus a $100M share repurchase authorization.
• Management highlighted continued product and go‑to‑market progress — advances in AlloHeme, AlloSure Liver, HistoMap Kidney, VANTx AI, and Epic integrations (target ~50% of volume via Epic by year‑end) — as strategic levers to extend leadership and drive repeat testing adoption.
• Near‑term risks and accounting variability include an expected LCD risk (modeled as a ~$7.5M revenue headwind in H2 2026), significant out‑of‑period revenue in Q1 that inflated revenue per test (Q1 included $260/test of out‑period collections), and guidance that still embeds the products business pending the planned Q3 close.

CareDx Stock Performance

Shares of CareDx stock traded down $0.12 on Thursday, reaching $20.68. The stock had a trading volume of 221,436 shares, compared to its average volume of 716,174. The business’s 50-day moving average price is $18.50 and its two-hundred day moving average price is $18.24. CareDx has a fifty-two week low of $10.96 and a fifty-two week high of $23.24. The stock has a market cap of $1.06 billion, a P/E ratio of -51.70 and a beta of 2.54.

Insider Transactions at CareDx

In related news, CEO John Walter Hanna, Jr. sold 10,282 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $21.12, for a total transaction of $217,155.84. Following the transaction, the chief executive officer owned 676,475 shares of the company’s stock, valued at approximately $14,287,152. The trade was a 1.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On CareDx

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp increased its position in CareDx by 6.7% during the fourth quarter. State Street Corp now owns 2,737,752 shares of the company’s stock worth $51,579,000 after acquiring an additional 171,303 shares during the period. Bamco Inc. NY increased its holdings in CareDx by 11.2% in the 2nd quarter. Bamco Inc. NY now owns 2,435,657 shares of the company’s stock valued at $47,593,000 after buying an additional 245,651 shares during the period. Deerfield Management Company L.P. bought a new stake in CareDx in the 3rd quarter valued at $31,857,000. Dimensional Fund Advisors LP increased its holdings in CareDx by 7.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,309,980 shares of the company’s stock valued at $24,681,000 after buying an additional 93,456 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of CareDx by 18.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after purchasing an additional 170,504 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts recently commented on CDNA shares. Wall Street Zen raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Saturday, April 25th. Weiss Ratings downgraded shares of CareDx from a “hold (c-)” rating to a “sell (d)” rating in a research report on Friday, February 27th. Wells Fargo & Company lifted their target price on shares of CareDx from $18.00 to $21.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. BTIG Research lifted their target price on shares of CareDx from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Craig Hallum cut shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 target price for the company. in a research note on Tuesday, January 6th. Two equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, CareDx presently has an average rating of “Hold” and an average target price of $28.00.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.